Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 12/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | PRKACA | P17612 | 1/20 | 0.38 |
| ▸ | FRK | P42685 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29453637 | 0.94 | CYP46A1 (0.53) | CYP46A1ALDH1A1 | |
| SCHEMBL22719256 | 0.94 | CYP46A1 (0.53) | CYP46A1ALDH1A1 | |
| SCHEMBL22719463 | 0.89 | CYP46A1 (0.48) | CYP46A1ALDH1A1 | |
| SCHEMBL22719464 | 0.89 | CYP46A1 (0.52) | CYP46A1ALDH1A1 | |
| SCHEMBL22719283 | 0.89 | CYP46A1 (0.65) | CYP46A1ALDH1A1 | |
| SCHEMBL29453733 | 0.88 | CYP46A1 (0.47) | CYP46A1ALDH1A1 | |
| SCHEMBL22719294 | 0.88 | CYP46A1 (0.47) | CYP46A1ALDH1A1 | |
| SCHEMBL22719351 | 0.82 | CYP46A1 (0.49) | CYP46A1ALDH1A1 | |
| SCHEMBL22719357 | 0.82 | CYP46A1 (0.64) | CYP46A1ALDH1A1 | |
| SCHEMBL29453666 | 0.82 | CYP46A1 (0.64) | CYP46A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022261510-A1 | NEUROACTIVE STEROID FOR THE TREATMENT OF ALZHEIMER'S DISEASE | SAGE THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| US-20220332699-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SAGE THERAPEUTICS, INC. | 2022-10-20 | — | — | US | disclosed |
| EP-3976186-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Sage Therapeutics, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| WO-2020243027-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SAGE THERAPEUTICS, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332699-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | CYP46A1, CYP26A1, CYP21A2 | CYP46A1 1/4885ALDH1A1 144/4885P2RX7 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.